BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Imamura Y, Watanabe M, Oki E, Morita M, Baba H. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. Ann Gastroenterol Surg 2021;5:46-59. [PMID: 33532680 DOI: 10.1002/ags3.12406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Shi L, Chen J, Wang B, Qi J, Chen G, Kang M, Zhang H, Jin X, Huang Y, Zhao Z, Chen J, Song B, Chen J. A novel risk score system for prognostic evaluation in adenocarcinoma of the oesophagogastric junction: a large population study from the SEER database and our center. BMC Cancer 2021;21:806. [PMID: 34256714 DOI: 10.1186/s12885-021-08558-1] [Reference Citation Analysis]
2 Luo F, Lin K. N6-methyladenosine (m6A) reader IGF2BP1 accelerates gastric cancer aerobic glycolysis in c-Myc-dependent manner. Exp Cell Res 2022;:113176. [PMID: 35489385 DOI: 10.1016/j.yexcr.2022.113176] [Reference Citation Analysis]
3 Yanagimoto Y, Kurokawa Y, Doki Y, Yoshikawa T, Boku N, Terashima M. Surgical and perioperative treatment strategy for resectable esophagogastric junction cancer. Jpn J Clin Oncol 2022:hyac019. [PMID: 35246684 DOI: 10.1093/jjco/hyac019] [Reference Citation Analysis]
4 Liu X, Jiang Q, Yue C, Wang Q. Clinicopathological Characteristics and Survival Predictions for Adenocarcinoma of the Esophagogastric Junction: A SEER Population-Based Retrospective Study. Int J Gen Med 2021;14:10303-14. [PMID: 34992445 DOI: 10.2147/IJGM.S341405] [Reference Citation Analysis]
5 Segna D, Brusselaers N, Glaus D, Krupka N, Misselwitz B. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis. Therap Adv Gastroenterol 2021;14:17562848211051463. [PMID: 34777575 DOI: 10.1177/17562848211051463] [Reference Citation Analysis]
6 Saito T, Kurokawa Y, Takahashi T, Yamamoto K, Yamashita K, Tanaka K, Makino T, Nakajima K, Eguchi H, Doki Y. Neoadjuvant docetaxel, oxaliplatin and S‑1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction. Gastric Cancer 2022. [PMID: 35488968 DOI: 10.1007/s10120-022-01300-1] [Reference Citation Analysis]